Lapatinib
Back to searchMolecule Structure
Scientific Name
Lapatinib
Description of the Drug
Lapatinib is an antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-positive breast cancer in patients who received prior chemotherapeutic treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01259
http://www.drugbank.ca/drugs/DB01259
Brand Name(s)
Tyverb
Company Owner(s)
Natco Pharma Ltd, Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Epidermal growth factor receptor erbB1 | SINGLE PROTEIN | INHIBITOR | CHEMBL203 |
| Receptor protein-tyrosine kinase erbB-2 | SINGLE PROTEIN | INHIBITOR | CHEMBL1824 |
Clinical Trial(s)
Unichem Links
| Atlas | lapatinib | ||
| SureChEMBL | SCHEMBL8100 | ||
| PharmGKB | PA152241907 | ||
| Human Metabolome Database | HMDB0015388 | ||
| DrugBank | DB01259 | ||
| PubChem: Thomson Pharma | 14911387 | ||
| PubChem | 208908 | ||
| LINCS | LSM-1051 | ||
| Nikkaji | J1.859.987B | ||
| PDBe | FMM | ||
| BindingDB | 5445 | ||
| EPA CompTox Dashboard | DTXSID7046675 | ||
| DrugCentral | 1548 | ||
| Brenda | 213440 | ||
| ChemicalBook | CB8855402 | ||
| Guide to Pharmacology | 5692 | ||
| rxnorm | TYKERB | LAPATINIB | LAPATINIB DITOSYLATE |
| ChEBI | 49603 | ||
| ZINC | ZINC000001550477 |
